MENINGOCOCCAL MENINGITIS ACWY FACTS


Meningococcal Meningitis ACWY "MENACTRA" is made by the vaccine manufacturer Sanofi Pasteur. This vaccine is recommended for ages 9 months - 55 years of age (3 doses recommended) This vaccine does not prevent N meningitides Serogroup B. Initial U.S approval: 2005


SYMPTOMS OF MENINGOCOCCAL MENINGITIS ACWY

Meningitis symptoms include sudden onset of fever, headache, and stiff neck. There are often other symptoms, such as Nausea, Vomiting, Photophobia (increased sensitivity to light), Altered mental status (confusion)


TRANSMISSION:

1. Close contact (coughing or kissing)


INGREDIENTS:

1. Watson Scherp media with casamino acid (AMINO ACIDS, PEPTIDES)

2. Modified culture medium containing Hydrolyzed Casein

3. Ammonium Sulfate - (INORGANIC SALT)

4. Sodium Phosphate - (INORGANIC SALT)

5. Formaldehyde - (TOXIC GAS)

6. Sodium Chloride - (SALT) 


YOU SHOULD NOT GET THIS VACCINATION IF:

1. If you have ever had a life-threatening allergic reaction after a previous dose of meningococcal ACWY vaccine, or any part of this vaccine

2. Safety and effectiveness of Menactra have not been established in children younger than 9 months of age, pregnant women, nursing mothers, and adults older than 55 years of age


CONTRAINDICTIONS:

1. Severe allergic reaction (eg, anaphylaxis) after a previous dose of a meningococcal capsular polysaccharide, diphtheria toxoid- or CRM197containing vaccine, or to any component of Menactra. 


WARNING:

1. We only vaccinate for 5 of the 12 types: Men B and Men A, C, Y and W-135

2. Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of Menactra.

3. Prior to administration, the healthcare provider should review the immunization history for possible vaccine sensitivity and previous vaccination-related adverse reactions to allow an assessment of benefits and risks. Epinephrine and other appropriate agents used for the control of immediate allergic reactions must be immediately available should an acute anaphylactic reaction occur.

4. Some individuals with altered immunocompetence, including some individuals receiving immunosuppressant therapy, may have reduced immune responses to Menactra.

5. Menactra may not protect all recipients

6. Syncope (fainting) has been reported following vaccination with Menactra. Procedures should be in place to prevent falling and manage syncopal reactions.

7. Pregnant woman received this vaccination: outcomes included 2 major birth defects and 6 miscarriages.

8. The effects of Menactra on breastfed infants or on milk production / excretion is unknown

9. Menactra has not been evaluated for carcinogenic (CANCER) or mutagenic potential (DNA MUTATION), or for impairment of male fertility (INFERTILITY)


DRUG INTERACTION:

1. Pneumococcal antibody responses to some serotypes in Prevnar (PCV7) were decreased following co-administration of Menactra and PCV7.